Gilead dou­bles down on HIV pre­ven­tion, treat­ment amid Covid set­backs and await­ing FDA de­ci­sion on long-act­ing can­di­date

Amid pre­dic­tions of HIV ad­vances un­rav­el­ing dur­ing Covid, Gilead Sci­ences is dou­bling down on pre­ven­tion, treat­ment op­tions and on-the-ground com­mu­ni­ty ef­forts, even as it awaits an FDA de­ci­sion on its long-act­ing can­di­date.

At the AIDS 2022 con­fer­ence be­gin­ning next week, Gilead will present new da­ta and stud­ies on HIV treat­ment Bik­tarvy and its long-act­ing PrEP and HIV can­di­date lenaca­pavir, but will al­so host a pan­el lay­ing out the de­tails — and im­por­tance — of com­mu­ni­ty col­lab­o­ra­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER